Get started

More results...

Filter by Content types
Filter by Geography

Alerts LATEST ALERTS

  • Europe Comagri approves the EC's hemp proposal ...
  • Italy Low-THC flowers do not create public health risk, court says ...
  • South Africa Country positioning itself as growing leader in cannabis and hemp ...
  • France Government collapse likely to slow down current proposals ...
  • Morocco Cannabis sector being integrated into national economy ...
  • Thailand Newly elected PM helped legalise cannabis in 2022, will he again? ...
  • Denmark Steps taken to legally enshrine medical cannabis pilot programme ...
  • Texas - United States Industry victory as bill to ban THC in hemp products dies in special session ...
  • Brazil Post-decriminalisation, new policy to offer support over punishment ...
  • Thailand Cannabis legalisation champion says he could be next prime minister ...
  • Texas - United States Cannabinoid-containing vape ban now in effect ...
  • Ecuador Commission approved to evaluate medical and recreational cannabis bill ...
News analysis

Jazz Pharmaceuticals buys Epidiolex manufacturer GW Pharma for $7.2bn

Written by || 3rd February 2021 || News analysis | Companies | Health and science | GeographiesEurope Ireland North America United Kingdom United States

GW Pharmaceuticals, the British manufacturer of the CBD-based epilepsy drug Epidiolex, has been acquired by Jazz Pharmaceuticals in a cash and shares deal worth over $7bn
Unlock access

Want the full analysis? Let's talk

We share insights with professionals we’re in contact with. Let us know a bit about your interest.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

I'm already a subscriber

Freddie Dawson

Senior contributing editor
Freddie studied at King’s College, London and City University and worked for publications including The Times, The Malay Mail, PathfinderBuzz and Solar Summary before joining the CannIntelligence team. He has extensive experience in covering fast-moving consumer goods (FMCG), manufacturing and technological innovation.

Our Key Benefits

The global cannabis market is in an opaque regulatory environment that requires professionals to be on top of industry developments to make informed decisions and optimise their strategy.

CannIntelligence provides organisations with leading market and regulatory data analysis to anticipate and understand market developments globally and the impact of regulatory changes to the business.

  • Stay informed of any legal and market change in the sector that impacts your organisation
  • Maximise resources by getting market and legal data analysis daily in one place
  • Make smart decisions by understanding how the regulatory and market landscape evolves
  • Anticipate risks in your decisions by monitoring regulatory changes that impact your organization

Want the full analysis? Let's talk

We share insights with professionals we’re in contact with. Let us know a bit about your interest.

"*" indicates required fields

Name*
*
This field is for validation purposes and should be left unchanged.

Sign up to our newsletter

Stay up-to-date with key regulatory news and receive complimentary data on a regular basis.